Key Drivers
- Strong liquidity
- Elevated leverage
- Large intangibles
AIAI Summary
Integer has shifted from a premium growth story to a tactical recovery/value trade: the stock's upside hinges on successful recovery of three underperforming product ramps (the primary 3–4% 2026 revenue headwind) and clear, sustained free‑cash‑flow improvement to de‑lever without cutting R&D. Actionable rule: monitor monthly/quarterly product adoption metrics, Q‑to‑Q FCF trends versus debt maturities, and any material litigation/refinancing developments—failure on ramps or a refinancing stress event should be a sell signal.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Elevated leverage
- •Large intangibles
ITGR shows strong liquidity and FCF with improving margins but carries high leverage, large intangibles and only modest returns versus a premium valuation.
Price Behavior
Key Price Behavior Insights:
- •Below short SMA
- •Mid‑range support
- •Clustered resistance
ITGR is range-bound with short-term downside pressure (last month SMA ~$85.30, last trade $84.10) and needs a hold above ~$85.3 and a clear break above $86–$87 to resume upside, while a decisive break below ~$83 would amplify downside risk.
Volatility with sharp swings between roughly $83 and $87 over the last month
Sentiment & News
Key News Insights:
- •Shareholder activism
- •Legal scrutiny
- •Institutional buying
Investor activism, board changes, and multiple law‑firm probes following a material guidance cut have driven heavy buying by some funds amid sharp share‑price weakness and active investor outreach.
The convergence of legal investigations and activist influence raises near‑term governance risk and could pressure the stock until board and disclosure issues are resolved
Similar Companies in Healthcare
Other companies in the same sector with AI ratings